17 Aug 2023
Redeye interviews Mathias Skalmstad about the licence agreement
Sprint Biosciences' acting CEO Mathias Skalmstad visited Redeye's studio and answered questions regarding the licence agreement for the VADA programme.
Press release
Comment from Redeye on the agreement